Impact of Brokerage Rating on Trevena, Inc.(TRVN)

Many Trevena, Inc.(TRVN) Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock. Trevena Inc was Initiated by Ladenburg Thalmann on Feb 2, 2017 to Buy, Price Target of the shares are set at $15.Trevena Inc was Initiated by H.C. Wainwright on Jan 9, 2017 to Buy, Price Target of the shares are set at $11.Trevena Inc was Initiated by Oppenheimer to Outperform on Jan 5, 2017.

Company has reported several Insider transactions to the SEC, on Nov 10, 2016, Carrie L. Bourdow (SVP, Chief Commercial Officer) purchased 4,000 shares at 4.34 per share price.On Nov 9, 2016, Maxine Gowen (CEO) purchased 12,500 shares at 4.10 per share price.On Nov 9, 2016, Yacoub Habib (SVP, Bus Dev & Corp Planning) purchased 5,000 shares at 4.12 per share price.

Trevena, Inc. (NASDAQ:TRVN) has received a short term rating of sell from experts at Zacks with a rank of 4. The stock has been rated an average of 1.11 by 9 Brokerage Firm. 8 Wall Street Firms have rated the stock as a strong buys. 1 stock experts have also suggested a buy rating.

Trevena, Inc. (NASDAQ:TRVN): The mean estimate for the short term price target for Trevena, Inc. (NASDAQ:TRVN) stands at $13.15 according to 10 Analysts. The higher price target estimate for the stock has been calculated at $16 while the lower price target estimate is at $11.

Trevena, Inc. (NASDAQ:TRVN) witnessed a decline in the market cap on Tuesday as its shares dropped 3.62% or 0.28 points. After the session commenced at $7.7, the stock reached the higher end at $7.71 while it hit a low of $7.41. With the volume soaring to 616,470 shares, the last trade was called at $7.45. The company has a 52-week high of $10. The company has a market cap of $416 million and there are 55,800,000 shares in outstanding. The 52-week low of the share price is $3.76.

Trevena, Inc. is a biopharmaceutical company. It focuses on discovering and developing therapeutics for G protein coupled receptors. The Companys product pipeline includes TRV027, TRV130, TRV734 and Delta opioid biased ligand which are in different clinical phases. Trevena, Inc. is based in King of Prussia, Pennsylvania.


Share this post

Leave a Reply